Hecel Aleksandra, Ostrowska Małgorzata, Stokowa-Sołtys Kamila, Wątły Joanna, Dudek Dorota, Miller Adriana, Potocki Sławomir, Matera-Witkiewicz Agnieszka, Dominguez-Martin Alicia, Kozłowski Henryk, Rowińska-Żyrek Magdalena
Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland.
Screening Laboratory of Biological Activity Tests and Collection of Biological Material, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
Pharmaceuticals (Basel). 2020 Sep 1;13(9):228. doi: 10.3390/ph13090228.
Zn(II) is an inhibitor of 's RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores-this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.
锌（II）是“[病毒名称]”的RNA依赖性RNA聚合酶的抑制剂，而氯喹和羟氯喹是锌（II）离子载体——这一说法让好奇的人有很多值得思考的地方。我们展示了氯喹（CQ）和羟氯喹（HCQ）治疗2019冠状病毒病（COVID-19）的首批临床试验结果，以及关于这两种化合物和锌（II）本身的抗冠状病毒特性的早期报告。其他美国食品药品监督管理局（FDA）批准的锌（II）离子载体也受到了相当多的关注，并被认为可能是治疗COVID-19的药物。
